Results 161 to 170 of about 33,286 (224)

Genomic and transmission dynamics of the 2024 Marburg virus outbreak in Rwanda. [PDF]

Nat Med
Butera Y, Mutesa L, Parker E, Muvunyi R, Umumararungu E, Ayitewala A, Musabyimana JP, Olono A, Sesonga P, Ogunsanya O, Kabalisa E, Adedokun O, Gahima N, Irankunda L, Mutezemariya C, Niyonkuru R, Uwituze A, Uwizera I, Kagame J, Umugwaneza A, Rwabuhihi J, Umwanankabandi F, Mbonitegeka V, Ntagwabira E, Kayigi E, Izuwayo G, Murenzi H, Mukankwiro T, Tuyiringire N, Uwimana JMV, Gasengayire A, Sindayiheba R, Onyeugo GU, Aragaw M, Gitundu L, Bigirimana R, Fallah M, Ejikeme A, Sembuche S, Kabanda A, Mugisha JC, Francis EES, Gashema P, Ndayisenga J, Rugamba A, Kanyabwisha F, Murenzi G, Happi A, Ngabonziza JCS, Gashegu M, Ahmed A, Bigirimana N, Rwagasore E, Semakula M, Rwabihama JP, Musanabaganwa C, Seruyange E, Nkeshimana M, Twagirumugabe T, Turatsinze D, Remera E, Gahamanyi N, Tessema SK, Mukagatare I, Nsanzimana S, Happi C, Muvunyi CM.   +66 more
europepmc   +1 more source

Exploration of African natural products as VP35 inhibitors to combat Marburg virus infection: Molecular docking, molecular dynamics, and quantum mechanical computations. [PDF]

PLoS One
Abdelrahman AHM, Mekhemer GAH, Sidhom PA, El-Tayeb MA, Khan S, Ibrahim MAA.   +5 more
europepmc   +1 more source

Identification of potential VP40 inhibitor of Marburg virus through molecular docking, pharmacokinetic analysis and molecular dynamics simulation. [PDF]

Sci Rep
Das R, Bhattarai A, Tamang B, Thakur N.
europepmc   +1 more source

Process Intensification for Recombinant Marburg Virus Glycoprotein Production Using <i>Drosophila</i> S2 Cells. [PDF]

Eng Life Sci
Göbel S, Mayerlen L, Eiser IY, Fichtmueller L, Clements D, Reichl U, Genzel Y, Lehrer A.   +7 more
europepmc   +1 more source

Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda. [PDF]

Sci Rep
Mugisha JC, Kayigi E, Gahamanyi N, Uwayo HD, Umwanankabandi F, Gashema P, Rwagasore E, Turatsinze D, Nkeshimana M, Gashegu M, Ntagwabira E, Makayoto L, Ngabonziza JCS, Mukagatare I, Tuyishime A, Rujeni N, Mutesa L, Seruyange E, Musafiri S, Twagirumugabe T, Harelimana JD, Muvunyi CM.   +21 more
europepmc   +1 more source

Thirteen-Year Sequelae of Marburg Virus Disease Survival: Persistent Cardiometabolic, Immunometabolic, and Haematological Alterations in the Absence of Psychological Morbidity. [PDF]

Pathogens
Serwanga J, Kaweesa RE, Ssebwana JK, Odoch G, Wayesu RR, Ntabadde AD, Mukisa D, Ejou P, FiloStudy Team, Lutwama JJ, Kaleebu P.   +10 more
europepmc   +1 more source

Marburg Virus Disease: Epidemiology, Immune Responses, and Innovations in Vaccination and Treatment for Enhanced Public Health Strategies. [PDF]

Pathogens
Dzinamarira T, Muvunyi CM.
europepmc   +1 more source

In-silico repurposing of antiviral compounds against Marburg virus: a computational drug discovery approach. [PDF]

In Silico Pharmacol
Singh RK, Sarkar K, Das RK.
europepmc   +1 more source

Detection of autoantibodies against exocrine pancreas by double immunodiffusion testing [PDF]

, 1990
Horbach, E., Kaiser, Doris, Otte, M., Rögener, W., Scriba, Peter Christian, Stöcker, W.   +5 more
core  

Marburg virus disease Mayhem: A new threat emerges in Rwanda. [PDF]

New Microbes New Infect
Kumar P, Jayan J, Balaraman AK, Pandey S, Brar M, Mehta R, Sah S.   +6 more
europepmc   +1 more source